Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q2 2022
Institutional positions in Damora Therapeutics, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- −2 vs. Q1 2022
- Shares held
- 9.10M
- −462.3K (−4.8%) vs. Q1 2022
- Total value
- $15.7M
- −$5.30M (−25.2%) vs. Q1 2022
- New holders
- 2
- 12 more added
- Sold out
- 4
- 4 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DMRA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 104 | $1.67B |
| Q1 2026 | 65 | $1.45B |
| Q4 2025 | 18 | $65.5M |
| Q3 2025 | 12 | $633.3K |
| Q2 2025 | 9 | $451.5K |
| Q1 2025 | 11 | $442.4K |
| Q4 2024 | 10 | $660.7K |
| Q3 2024 | 10 | $1.56M |
| Q2 2024 | 22 | $1.91M |
| Q1 2024 | 26 | $3.09M |
| Q4 2023 | 22 | $2.77M |
| Q3 2023 | 22 | $3.92M |
| Q2 2023 | 27 | $25.7M |
| Q1 2023 | 26 | $17.8M |
| Q4 2022 | 22 | $10.2M |
| Q3 2022 | 26 | $17.3M |
| Q2 2022 | 23 | $15.7M |
| Q1 2022 | 25 | $21.0M |
| Q4 2021 | 26 | $30.5M |
| Q3 2021 | 25 | $37.2M |
| Q2 2021 | 27 | $57.4M |
| Q1 2021 | 19 | $82.9M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Damora Therapeutics, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Simplex Trading, LLC | 485 | $0 | 0.00% | +411+555.4% | Added |
| Curi Capital | 76 | $0 | 0.00% | +76 | New |
| JPMorgan Chase & Co | 854 | $1.00K | 0.00% | −912−51.6% | Reduced |
| Tower Research Capital LLC (TRC) | 2,592 | $4.00K | 0.00% | +2,186+538.4% | Added |
| Wells Fargo & Company | 2,986 | $5.00K | 0.00% | +9+0.3% | Added |
| BlackRock Inc. | 14,164 | $25.0K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 20,551 | $36.0K | 0.00% | +1,545+8.1% | Added |
| Millennium Management LLC | 30,357 | $53.0K | 0.00% | +1,476+5.1% | Added |
| Vanguard Group Inc | 34,219 | $59.0K | 0.00% | +8,511+33.1% | Added |
| Bank of America Corp | 37,012 | $64.0K | 0.00% | +699+1.9% | Added |
| Federated Hermes, Inc. | 40,000 | $69.0K | 0.00% | +14,000+53.8% | Added |
| State Street Corp | 44,906 | $78.0K | 0.00% | +1,900+4.4% | Added |
| Marquette Asset Management, LLC | 60,244 | $104.0K | 0.03% | +14,479+31.6% | Added |
| Two Sigma Investments, LP | 63,295 | $110.0K | 0.00% | −80,371−55.9% | Reduced |
| Two Sigma Advisers, LP | 104,900 | $181.0K | 0.00% | −38,800−27.0% | Reduced |
| Geode Capital Management, LLC | 106,136 | $183.0K | 0.00% | +8,951+9.2% | Added |
| Bridgeway Capital Management, LLC | 173,100 | $299.0K | 0.01% | −10,000−5.5% | Reduced |
| Laurion Capital Management LP | 190,652 | $330.0K | 0.01% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 246,711 | $427.0K | 0.00% | +20,547+9.1% | Added |
| MAI Capital Management | 320,860 | $555.0K | 0.01% | +320,860 | New |
| Cormorant Asset Management, LP | 1,020,238 | $1.76M | 0.14% | 00.0% | Unchanged |
| Novo Holdings A/S | 2,497,791 | $4.32M | 0.21% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 4,090,937 | $7.08M | 0.14% | 00.0% | Unchanged |
| Janus Henderson Group PLC | 0 | $0 | 0.00% | −724,523−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −2,495−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −242−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −563−100.0% | Sold out |